Oppenheimer Maintains Outperform on Astria Therapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and raises the price target from $25 to $26.
August 13, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Astria Therapeutics and raises the price target from $25 to $26.
The raised price target and maintained Outperform rating from a reputable analyst at Oppenheimer is likely to positively influence investor sentiment and drive short-term price appreciation for Astria Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100